Society for Translational Oncology navigateright Episode
David Liu, MD, MPH, MS
Massachusetts General Hospital
The development of immune checkpoint blockade (ICB) has revolutionized the treatment of cancer. However, the ability to identify which patients will have durable benefit and to understand how tumors develop resistance to ICB is critical to improving patient management and outcomes. Here, we present two complementary approaches representing parallel paths to dissecting response and resistance to ICB.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.